NVL-330, a selective HER2 tyrosine kinase inhibitor, in patients with advanced or metastatic HER2-altered non-small cell lung cancer: The phase 1 HEROEX-1 study.

Authors: Xiuning Le, Zofia Piotrowska, Alexander I. Spira, Christina S. Baik, Maria Quintos Baggstrom, Gerald Steven Falchook, Joel W. Neal, Shirish M. Gadgeel, Gilberto Lopes, Melissa Lynne Johnson, Jonathan W. Riess, Danny Nguyen, Lisa Morelli, Danieska Sandino, Steven Margossian, Vivek Upadhyay, Fernando Santini

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps8665

Source: Full article

---

Abstract

TPS8665